Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7
Personalized Semaglutide + Glycine is available as an injectable medication
Given the observed increased risk of colorectal cancer among patients receiving GLP-1 receptor agonists, clinicians should approach long-term prescribing of these agents with careful consideration, particularly in individuals with additional risk factors for colorectal cancer, such as a family history, obesity, inflammatory bowel disease, or long-standing type 2 diabetes
Why is berberine not approved by the FDA
Across premenopausal, perimenopausal, and postmenopausal women, tirzepatide produced similar reductions in body weight, waist circumference, and central adiposity